Trial Profile

Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2019 According to a VistaGen Therapeutics media release, the company will continue to examine the full dataset from this study to evaluate effects on other endpoints and pharmacokinetics.
14 Nov 2019 Topline results presented in a VistaGen Therapeutics media release.
08 Oct 2019 According to a VistaGen Therapeutics media release, the company announced that the last patient has completed the dosing. The company remains on track to report the top line results of this study before the end of 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com